Compare Bristol-Myers Squibb Co (BMY) vs Dropbox Inc (DBX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Dropbox Inc — how do they compare? Bristol-Myers Squibb Co trades at $58.56 (market cap $116.30B), while Dropbox Inc trades at $30.39 (market cap $6.99B). The key difference: Bristol-Myers Squibb Co is far larger — about 16.6× Dropbox Inc's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Dropbox Inc pays none. Which is the better fit depends on your goals.
| BMY | DBX | |
|---|---|---|
Market Cap | $116.30B | $6.99B |
Sector | Health | Technology |
52-Week High | $62.37 | $32.17 |
52-Week Low | $42.60 | $22.06 |
Enterprise Value | $152.24B | $9.71B |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Dropbox (DBX) trades at $29.58, up 1.34% on the day, near the analyst consensus price target of $30. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate potential overbought conditions. Fundamentally, the company maintains robust profitability with a net income margin of 18.71% and has beaten earnings estimates for three consecutive quarters. Recent news highlights a new $900 million stock repurchase program and a CEO transition plan announced in May 2026.
The outlook is balanced with solid fundamentals and shareholder returns offset by high debt levels and mixed analyst sentiment. Investment appeal lies in consistent earnings beats and capital return initiatives, but risks include elevated leverage and competitive pressures in cloud storage. The stock presents a moderate opportunity with cautious optimism warranted given its valuation near target prices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Dropbox Inc
Dropbox is a leading provider of cloud-storage and content collaboration tools with an emphasis on individuals and SMB. The company was founded in 2007 and was a pioneer in cloud storage and cross-platform file syncing. Utilizing inorganic and organic means, the firm has been working on diversifying its product mix and pivoting away from the cloud-storage space.
Read more on DBX →
